Core Insights - Genvor, Inc. has appointed Dr. George Stavrides as Executive Vice President, Business Development & Commercialization to enhance its strategic partnerships and market expansion efforts in sustainable agriculture [1][2] Company Overview - Genvor, Inc. is a biotechnology company focused on developing peptide-based solutions for crop protection and plant health, aiming to promote sustainable agriculture and reduce chemical inputs [4] Leadership Experience - Dr. Stavrides has over 15 years of experience in agrochemicals and biologicals, previously serving as Global Product Management Lead at Syngenta, where he managed over 500 biological product concepts and oversaw more than 50 product launches globally, resulting in a quadrupling of revenues over seven years [2][3] Strategic Focus - Dr. Stavrides will concentrate on expanding Genvor's commercial strategy, including strategic partnerships, licensing agreements, and collaborations with global agricultural companies [1][3] Industry Impact - The appointment of Dr. Stavrides is expected to accelerate Genvor's commercialization efforts and enhance its ability to address unmet grower needs through innovative biological technologies [3]

Woodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the 3rd Annual DealFlow Discovery Conference, taking place January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. Genvor Co-Founder Clayton Yates, MS, Ph.D. will deliver a company presentation on January 28 at 11:00 AM EST and will be available for one-on-one meeti ...

WOODLAND, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that Chad Pawlak, Chief Executive Officer, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11th. DATE: December 11th TIME: 12:30 pm ETLINK: REGISTER HEREAvailable for 1x1 meetings following the presentation. Schedule 1x1 Meetings here This will be a live, interactive online e ...

Core Insights - Genvor, Inc. has been granted U.S. Patent No. 12,458,684 for transgenic corn expressing antifungal peptide AGM182, aimed at combating fungal infections in maize [1][2][3] Company Overview - Genvor is focused on AI-accelerated peptide technology for sustainable agriculture, utilizing its proprietary BioCypher™ Algorithm to design next-generation antimicrobial peptides [1][6] - The company aims to provide scalable agricultural solutions that enhance crop protection and optimize agricultural outcomes [6] Patent Details - The patent covers biological compositions that reduce Aspergillus flavus, a fungal pathogen that produces aflatoxins, which can contaminate corn and other crops [2][4] - Research indicates that the technology also shows activity against other mycotoxin-producing fungi, including those from Fusarium species [2][4] Economic Impact - Economic losses from fungal diseases in corn in the U.S. are estimated between $3 billion to $5 billion annually, considering yield reductions and quality degradation [3] - Aflatoxin contamination can lead to market impacts ranging from approximately $52 million in lower-risk years to as much as $1.68 billion in high-risk years [3] Research Validation - Published research validates the effectiveness of AGM182 in transgenic corn seeds, demonstrating a 76–98% reduction in total aflatoxin contamination without adverse effects on plant growth or yield [5][7] - The technology reflects decades of foundational research and aims to deliver safe and effective peptide technologies for global agriculture [5]

Core Insights - Genvor, Inc. has regained active OTCQB trading status, which will facilitate capital formation as the company scales field trials globally [1][2] - The company is advancing four active research and development collaborations across Europe, Brazil, and the United States, focusing on peptide-based formulations for sustainable agriculture [2][3] Company Developments - Genvor has opened a new laboratory in Woodland, California, to support research and development for foliar and peptide-based formulations [3] - The company is actively collaborating on projects that aim to enhance crop resilience and performance under various field conditions [2][4] Technology and Innovation - Genvor utilizes an AI-accelerated peptide design platform, the BioCypher Algorithm, which integrates computational biology and machine learning to create peptides that improve agricultural outcomes [5] - The company holds 2 issued U.S. patents related to antimicrobial and nutrient-enhancing peptides, with 24 proprietary peptides currently in active development [5]